Cara Therapeutics Stock News

Charles Schwab Investment Management Inc. grew its holdings in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Sec

Cara Therapeutics Inc (NASDAQ:CARA)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $11.29 and last traded at $11.60, with a volume of 9561 shar

Analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to announce earnings of ($0.64) per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Cara Therapeut

Cara Therapeutics (NASDAQ:CARA) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports. Several ot

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Wall Street analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to announce $4.83 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Cara Therapeutic

The "Fast Money" traders share their first moves for the market open.

Barclays PLC increased its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 18.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange C

Cara Therapeutics Inc (NASDAQ:CARA) traded down 9.6% on Monday following insider selling activity. The stock traded as low as $13.14 and last traded at $13.81, 560,875 shares were traded during tradin

With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. Since the end of February, the major U.S. indexes have experienced violent swings in eit

With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. Since the end of February, the major U.S.

The "Fast Money" traders share their first moves for the market open.

Cara Therapeutics Inc (NASDAQ:CARA) Director Jeffrey L. Ives sold 2,500 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $16.00, for a total va

The "Fast Money" traders share their first moves for the market open.

The "Fast Money" traders share their first moves for the market open.